A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Two of the most common types of leukemias in adults are acute myeloid leukemia (AML) and chronic lymphocytic ... can ...

People at high risk of acute myeloid leukaemia (AML) can be identified years in advance, but there is currently no treatment ...

I don't usually talk about my cancer diagnosis. But as a physician-scientist who survived leukemia at 18 years old and now ...

Acute myeloid leukemia (AML) is a cancer that impacts the blood and bone marrow ... This overproduction crowds out normal blood cells, leading to symptoms such as fatigue, frequent infections, and ...

Acute myeloid leukemia (AML) is one of the most common types of leukaemia among adults. A major challenge in developing chimeric antigen receptor (CAR)-engineered cell therapies for acute myeloid ...

However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.

However, it has proven difficult to identify such specific antigens in certain cancer types, including acute myeloid leukemia (AML). AML patients are often treated using allogeneic hematopoietic stem ...

The journey of fighting Acute Myeloid Leukemia (AML) in India encompasses severe physical and emotional challenges for both patients and caregivers. Integrating mental health support into cancer ...

A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.